Axitinib
- Generic Name
- Axitinib
- Brand Names
- Inlyta, Axitinib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C22H18N4OS
- CAS Number
- 319460-85-0
- Unique Ingredient Identifier
- C9LVQ0YUXG
- Background
Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation V...
- Indication
Used in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer.
- Associated Conditions
- Advanced Renal Cell Carcinoma, Advanced Thyroid cancer
- Associated Therapies
- First Line Chemotherapy
Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib
- Conditions
- Interventions
- First Posted Date
- 2012-02-28
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 24
- Registration Number
- NCT01540526
- Locations
- 🇺🇸
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2012-02-16
- Last Posted Date
- 2018-05-09
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 25
- Registration Number
- NCT01533948
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Study of Axitinib and Temsirolimus in Solid Tumors
- First Posted Date
- 2012-02-08
- Last Posted Date
- 2015-04-13
- Lead Sponsor
- Emory University
- Target Recruit Count
- 13
- Registration Number
- NCT01529138
- Locations
- 🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States
Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients
- Conditions
- Interventions
- First Posted Date
- 2012-01-11
- Last Posted Date
- 2017-09-19
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 1
- Registration Number
- NCT01508117
- Locations
- 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States
A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)
- Conditions
- Interventions
- First Posted Date
- 2011-12-13
- Last Posted Date
- 2019-09-24
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 70
- Registration Number
- NCT01490866
- Locations
- 🇺🇸
Nebraska Methodist Hospital, Omaha, Nebraska, United States
🇺🇸NEA Baptist Clinic, Jonesboro, Arkansas, United States
🇺🇸Atlantic Health System, Summit, New Jersey, United States
Assessment of Tumor Vascular Effects of Axitinib With Dynamic Ultrasonography in Patients With Metastatic Colorectal Cancer
- First Posted Date
- 2011-12-06
- Last Posted Date
- 2016-02-10
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 27
- Registration Number
- NCT01486251
- Locations
- 🇫🇷
Institut gustave roussy, Villejuif, France
Axitinib as Maintenance Treatment in Patients With Metastatic CRC
- First Posted Date
- 2011-12-01
- Last Posted Date
- 2016-05-12
- Target Recruit Count
- 84
- Registration Number
- NCT01483638
- Locations
- 🇪🇸
Spanish Cooperative Group for Digestive Tumour Therapy, Madrid, Spain
Clinical Study With Axitinib In Advanced Kidney Cancer, Who Have Failed First Line Treatment
- Conditions
- First Posted Date
- 2011-11-17
- Last Posted Date
- 2014-05-30
- Lead Sponsor
- Pfizer
- Registration Number
- NCT01473043
- Locations
- 🇨🇦
Pfizer Investigational Site, Montreal, Quebec, Canada
A Study of Axitinib in Advanced Carcinoid Tumors
- First Posted Date
- 2011-09-15
- Last Posted Date
- 2018-10-02
- Target Recruit Count
- 30
- Registration Number
- NCT01435122
- Locations
- 🇺🇸
University of California San Francisco (UCSF), San Francisco, California, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis
- Conditions
- Interventions
- First Posted Date
- 2011-08-04
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 73
- Registration Number
- NCT01409200
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.